Precision health technology developer HealthLytix has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its RSI-MRI+ prostate imaging software.
The software is designed to enhance the visibility of restricted water in body tissue through an advanced diffusion MRI technique called restriction spectrum imaging (RSI). RSI's combination of artificial intelligence and a tissue microstructure model could lead to the early detection and diagnosis of prostate cancer, according to the company.
HealthLytix plans to debut the software at the upcoming annual RSNA 2019 meeting in Chicago.
